Inclusion Criteria:  Pathologically-proven diagnosis of squamous cell carcinoma of the oropharynx, larynx, or hypopharynx. clinically or radiographically evident measurable disease at the primary site and/or nodal stations diagnostic or therapeutic transoral resection for a T1-2 tonsil or base of tongue cancer. Clinical stage I-IVB (AJCC, 7th edition); stages I-II glottic cancer are excluded Age ≥ 18 years. ECOG Performance Status 0-2 All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Negative serum or urine pregnancy test Neck CT and/or neck MRI, and PET-CT (at least skull-to-thigh). Ability to understand and the willingness to sign a written informed consent.  Exclusion Criteria:  Distant metastasis. Inability to undergo PET-CT. Stage I and II glottic carcinoma. Gross total excision of both the primary and nodal disease. Synchronous non-skin cancer primaries outside of the oropharynx, larynx, and hypopharynx except for low- and intermediate-risk prostate cancer and synchronous well-differentiated thyroid cancer Prior invasive malignancy with an expected disease-free interval of less than 3 years. Prior systemic chemotherapy for the study cancer; Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields. Subjects may not be receiving any other investigational agents. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy agents in this study (if necessary). Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations pregnant or nursing women History of severe immunosuppression, including HIV, and organ or autologous or allogeneic stem cell transplant.